Matthew Zirui Tay graduated in Immunology from Brown University, USA, and then obtained his PhD at Duke University, USA in 2018, where he studied the Fc effector functions of antibodies against HIV-1. He returned as a postdoctoral fellow at the Singapore Immunology Network (SIgN), where he continued research work on antibodies, malaria, and subsequently SARS-CoV-2. He is now a Principal Investigator at the A*STAR Infectious Diseases Labs leading the Antimicrobial Biologics Laboratory, where he is exploring novel biotherapeutics discovery against coronaviruses and other emerging pathogens for the purposes of pandemic preparedness. His research combines rigorous high-throughput screening platforms with biological and structural insights from viral evolutionary diversity to efficiently identify broad-acting biotherapeutic candidates.